A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that PKDL develop after SSG as well as after Miltefosine mono-therapy for VL; anti-inflammatory cytokines such as IL-10, TGF-β, serum lipids play key role for its pathogenesis & PKDL patients are genetically predisposed; diagnostic tool based on immunofluorescence technique will be more sensitive than slit skin examination for diagnosis of PKDL.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
• Collaborator: University of Nagasaki.
• Treatments: Miltefosine

Criteria

Inclusion Criteria:

• History of Visceral Leishmaniasis

• Presence of hypopigmented rash

• Rk39 strip test positive

• Written informed consent from the participant

Exclusion Criteria:

• Any medical condition that may affect the safety of the patient during study procedure

• Any condition which comprises the ability to comply the study procedure

• Presence of splenomegaly

• Posotive skin smear for mycobacterium leprae

• Positive skin smear for fungus

• Pregnancy test positive